{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:08:14Z","timestamp":1781622494830,"version":"3.54.5"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients who have suffered an atypical femoral fracture while on bisphosphonates or denosumab may continue to be at risk for typical osteoporotic fractures. There are no studies to provide guidance on safe treatment for such patients. Instead, using an illustrative case, 5 principles of management are provided that may lead to decreased osteoporotic fracture risk. The first principle is to discontinue the anti-resorptive medications, which may be challenging for the patient on denosumab because of rebound vertebral fractures reported in patients stopping denosumab. The second principle is to maximize non-pharmacologic management to reduce falls and fractures. Home safety, other methods of fall risk reduction, adequate nutrition, and an exercise prescription should help reduce fracture risk. Investigating potential secondary causes of osteoporosis, particularly if the original workup was not comprehensive, is the third principle because treatment of some specific causes may lower fracture risk. Reviewing the medication list is the fourth principle, with the goal of eliminating drugs that may increase fracture risk, and considering thiazides for some patients, which may lower fracture risk. Finally, some patients may benefit from anabolic therapy. One potential (but not FDA-approved) method is to use long-term cyclic teriparatide or abaloparatide on a 3-mo on, 3-mo off schedule. Tailoring the approach to each patient is important, based on the 5 clinical principles, in the absence of evidence-based management recommendations.<\/jats:p>","DOI":"10.1093\/jbmr\/zjae150","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T03:34:31Z","timestamp":1726630471000},"page":"1711-1715","source":"Crossref","is-referenced-by-count":10,"title":["Treating osteoporosis in patients with atypical femoral fracture"],"prefix":"10.1093","volume":"39","author":[{"given":"Robert A","family":"Adler","sequence":"first","affiliation":[{"name":"Endocrinology Section , , Richmond, VA 23249 ,","place":["United States"]},{"name":"Richmond Veterans Affairs Medical Center , , Richmond, VA 23249 ,","place":["United States"]},{"name":"Division of Endocrinology , , Richmond, VA 23298 ,","place":["United States"]},{"name":"Virginia Commonwealth University , , Richmond, VA 23298 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"issue":"1","key":"2024121305182511100_ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024121305182511100_ref2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/jbmr.4461","article-title":"Fracture risk following an atypical femoral fracture","volume":"37","author":"Begin","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2024121305182511100_ref3","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.bone.2011.06.027","article-title":"Prolonged bisphosphonate release after treatment in women with osteoporosis","volume":"49","author":"Peris","year":"2011","journal-title":"Relationship with bone turnover Bone"},{"issue":"1","key":"2024121305182511100_ref4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.4453","article-title":"Bone mineral density and bone turnover 10 years after a single 5 mg dose or two 5-yearly lower doses of zoledronate in osteopenic older women: an open-label extension of a randomized controlled trial","volume":"37","author":"Grey","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2024121305182511100_ref5","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/jbmr.448","article-title":"Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study","volume":"26","author":"Brown","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024121305182511100_ref6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11914-022-00771-6","article-title":"Denosumab discontinuation","volume":"21","author":"Solling","year":"2023","journal-title":"Curr Osteoporos Rep"},{"issue":"11","key":"2024121305182511100_ref7","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024121305182511100_ref8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","article-title":"Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study","volume":"34","author":"Tutaworn","year":"2023","journal-title":"Osteoporos Int"},{"issue":"7","key":"2024121305182511100_ref9","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study","volume":"36","author":"Solling","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2024121305182511100_ref10","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00198-022-06388-w","article-title":"Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women","volume":"33","author":"Ha","year":"2022","journal-title":"Osteoporos Int"},{"issue":"4","key":"2024121305182511100_ref11","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.jocd.2021.01.006","article-title":"Efficacy of antiosteoporosis medications in patients with rebound-associated fractures after denosumab discontinuation","volume":"24","author":"Anastasilakis","year":"2021","journal-title":"J Clin Densitom"},{"issue":"9999","key":"2024121305182511100_ref12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomized controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"2024121305182511100_ref13","doi-asserted-by":"publisher","first-page":"e10512","DOI":"10.1002\/jbm4.10512","article-title":"Skeletal responses to romosozumab after 12 months of denosumab","volume":"5","author":"McClung","year":"2021","journal-title":"JBMR Plus"},{"issue":"8","key":"2024121305182511100_ref14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N Engj J Med"},{"issue":"1","key":"2024121305182511100_ref15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2024121305182511100_ref16","doi-asserted-by":"publisher","first-page":"e1917789","DOI":"10.1001\/jamanetworkopen.2019.17789","article-title":"Vitamin D and calcium for the prevention of fracture: a systematic review and meta-analysis","volume":"2","author":"Yao","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"7","key":"2024121305182511100_ref17","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/jbmr.2536","article-title":"Serum-25-hydroxyvitamin D levels: variability, knowledge gaps, and the concept of a desirable range","volume":"30","author":"Gel-H","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024121305182511100_ref18","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/jbmr.2836","article-title":"Risk factors for hip fracture in older men: the osteoporotic fractures in men study (MrOS)","volume":"31","author":"Cauley","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024121305182511100_ref19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/jgs.15626","article-title":"Association between cataract and risks of osteoporosis and fracture: a nationwide cohort study","volume":"67","author":"Huang","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"2024121305182511100_ref20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1249\/JES.0000000000000281","article-title":"Exercise prescription for osteoporosis: back to basics","volume":"50","author":"Beck","year":"2022","journal-title":"Exerc Sport Sci Rev"},{"issue":"7","key":"2024121305182511100_ref21","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00198-019-05252-8","article-title":"Hip protectors are cost-effective in the prevention of hip fractures in patients with high fracture risk","volume":"31","author":"De Bot","year":"2020","journal-title":"Osteoporos Int"},{"issue":"3","key":"2024121305182511100_ref22","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1530\/EJE-15-0118","article-title":"Secondary osteoporosis: pathophysiology and management","volume":"173","author":"Mizra","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2024121305182511100_ref23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11914-022-00717-y","article-title":"Evaluating patients for secondary causes of osteoporosis","volume":"20","author":"Lewiecki","year":"2022","journal-title":"Curr Osteoporos Rep"},{"issue":"10","key":"2024121305182511100_ref24","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1210\/jc.2002-020275","article-title":"Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women","volume":"87","author":"Tannenbaum","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024121305182511100_ref25","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00198-010-1421-0","article-title":"Osteoporosis in men: the value of laboratory testing","volume":"22","author":"Ryan","year":"2011","journal-title":"Osteoporos Int"},{"issue":"1","key":"2024121305182511100_ref26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00198-015-3356-y","article-title":"Clinical utility of routine laboratory testing to identify possible secondary causes in older men with osteoporosis: the osteoporotic fractures in men (MrOS) study","volume":"27","author":"Fink","year":"2016","journal-title":"Osteoporos Int"},{"issue":"6","key":"2024121305182511100_ref27","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00415-010-5511-x","article-title":"Copper deficiency myelopathy","volume":"257","author":"Jaiser","year":"2010","journal-title":"J Neurol"},{"issue":"1","key":"2024121305182511100_ref28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3949\/ccjm.85a.16090","article-title":"Idiopathic hypercalciuria: can we prevent stones and protect bones?","volume":"85","author":"Ryan","year":"2018","journal-title":"Cleve Clin J Med"},{"issue":"5","key":"2024121305182511100_ref29","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1056\/NEJM199002013220502","article-title":"Thiazide diuretic agents and the incidence of hip fracture","volume":"322","author":"LaCroix","year":"1990","journal-title":"N Engl J Med"},{"issue":"7","key":"2024121305182511100_ref30","doi-asserted-by":"publisher","first-page":"516","DOI":"10.7326\/0003-4819-133-7-200010030-00010","article-title":"Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults","volume":"133","author":"LaCroix","year":"2000","journal-title":"Ann Intern Med"},{"issue":"4","key":"2024121305182511100_ref31","doi-asserted-by":"crossref","first-page":"bvad013","DOI":"10.1210\/jendso\/bvad013","article-title":"The eucalcemic patient with elevated parathyroid hormone levels","volume":"7","author":"Shaker","year":"2023","journal-title":"J Endocr Soc"},{"issue":"1","key":"2024121305182511100_ref32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jocd.2018.03.004","article-title":"Glucocorticoid-induced osteoporosis: management challenges in older patients","volume":"22","author":"Adler","year":"2019","journal-title":"J Clin Densitom"},{"issue":"12","key":"2024121305182511100_ref33","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1002\/art.42646","article-title":"2022 American College of Rheumatology Guideline of the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"75","author":"Humphrey","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"2024121305182511100_ref34","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1111\/jgh.15879","article-title":"Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: a nationwide population-based and multicenter cohort study using a common data model","volume":"37","author":"Park","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"2024121305182511100_ref35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00198-019-05206-0","article-title":"Proton pump inhibitors and fracture risk. The HUNT study, Norway","volume":"31","author":"Hoff","year":"2020","journal-title":"Osteoporos Int"},{"issue":"7","key":"2024121305182511100_ref36","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"2024121305182511100_ref37","doi-asserted-by":"publisher","first-page":"e2244652","DOI":"10.1001\/jamanetworkopen.2022.44652","article-title":"Association of glucose-lowering drugs with outcomes in patients with diabetes before hospitalization for COVID-10: a systematic review and network meta-analysis","volume":"5","author":"Zhu","year":"2022","journal-title":"JAMA Open Netw"},{"issue":"4","key":"2024121305182511100_ref38","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF01774014","article-title":"A randomized, double-masked, placebo-controlled trial of chlorthalidone and bone loss in elderly women","volume":"5","author":"Wasnich","year":"1995","journal-title":"Osteoporos Int"},{"issue":"11","key":"2024121305182511100_ref39","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/jbmr.4677","article-title":"Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the Fifth International Workshop","volume":"37","author":"Bilezikian","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024121305182511100_ref40","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1161\/HYPERTENSIONAHA.123.21274","article-title":"Skin cancer and hydrochlorothiazide: novel population-based analyses considering personal risk factors including race\/ethnicity","volume":"80","author":"Birck","year":"2023","journal-title":"Hypertension"},{"issue":"1","key":"2024121305182511100_ref41","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12916-022-02419-9","article-title":"Associations of thiazide use with skin cancers: a systematic review and meta-analysis","volume":"20","author":"Shao","year":"2022","journal-title":"BMC Med"},{"issue":"5","key":"2024121305182511100_ref42","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1210\/clinem\/dgz295","article-title":"Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European Calcified Tissue Society","volume":"105","author":"Van de Laarschot","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2024121305182511100_ref43","doi-asserted-by":"crossref","first-page":"e068033","DOI":"10.1136\/bmj-2021-068033","article-title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomized clinical trials","volume":"381","author":"Handel","year":"2023","journal-title":"BMJ"},{"key":"2024121305182511100_ref44","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.bone.2018.10.020","article-title":"Administration of teriparatide for four years cyclically compared to two years daily in treatment na\u00efve and alendronate treated women","volume":"120","author":"Cosman","year":"2019","journal-title":"Bone"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjae150\/60338376\/zjae150.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/39\/12\/1711\/60914043\/zjae150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/39\/12\/1711\/60914043\/zjae150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T05:18:37Z","timestamp":1734067117000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/39\/12\/1711\/7771863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,9,24]]},"published-print":{"date-parts":[[2024,11,29]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjae150","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,9,24]]}}}